Roche eyes alternate mode of administration for Ocrevus in MS
The investigation combines Ocrevus’ subcutaneous formulation with Halozyme’s drug delivery technology.
The investigation combines Ocrevus’ subcutaneous formulation with Halozyme’s drug delivery technology.
What's Your Reaction?
